At the $16 midpoint, the company anticipates net proceeds of $134.5 million, potentially climbing to $155.4 million if underwriters fully exercise their option for an additional 1.41 million shares. These funds are slated to support clinical operations through the second half of 2028, bolstering the firm's existing capital reserves as it tackles conditions with limited current therapeutic options.
In section Market Quotes
Aspen Neuroscience Targets $155 Million in Nasdaq IPO
San Diego-based biotech firm Aspen Neuroscience is setting its sights on the public markets, planning to sell 9.4 million shares at a valuation range of $15 to $17 per share. The clinical-stage company aims to secure up to $155.4 million to fuel its research into neurodegenerative disease treatments.
Following the offering, Aspen expects to have 30.5 million shares outstanding, resulting in a market capitalization of approximately $488 million at the midpoint price. The company has filed to list its common stock on the Nasdaq Global Select Market under the ticker symbol ASPE.
Comments (0)
No comments yet. Be the first!